Medtronic's diabetes breakthrough puts woes in past with soaring sales

18 months after the device was approved, the company says it will be able to meet demand

sugar, diabetes, injection
Photo: Shutterstock

Medtronic Plc’s diabetes breakthrough is finally starting to pay off. The diabetes division led the medical-device company’s sales growth last quarter, with a 17 per cent increase. The gain followed more than a year of mishaps that had prevented Medtronic from meeting surging demand for its latest device -- an artificial pancreas that takes over much of the constant attention diabetics must devote to controlling their blood sugar levels. “I do expect this to be a pivot point in many ways for diabetes,” Chief Executive Officer Omar Ishrak said in a ...